Investigational CEACAM5-directed antibody-drug conjugate (also known as SGN-CEACAM5C; SAR445953) with a camptothecin-class topoisomerase I inhibitor payload; binds CEACAM5 on tumor cells, is internalized, and releases payload to induce DNA damage and cell death.